Berdel, Andrew F.
Koch, Raphael http://orcid.org/0000-0002-5581-5122
Gerss, Joachim http://orcid.org/0000-0003-3489-683X
Hentrich, Marcus
Peceny, Rudolf
Bartscht, Tobias
Steffen, Björn
Bischoff, Marina
Spiekermann, Karsten
Angenendt, Linus
Mikesch, Jan-Henrik
Kewitz, Tobias
Butterfass-Bahloul, Trude
Serve, Hubert
Lenz, Georg
Berdel, Wolfgang E.
Krug, Utz
Schliemann, Christoph http://orcid.org/0000-0003-1755-9583
Funding for this research was provided by:
Boehringer Ingelheim
Westfälische Wilhelms-Universität Münster
Article History
Received: 15 October 2022
Accepted: 4 November 2022
First Online: 18 November 2022
Declarations
:
: The study was approved by the joined Ethics Committee of the Physicians Chamber of Westphalia-Lippe and the University of Muenster, Germany, and conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Guideline for Good Clinical Practice across 10 sites in Germany. Written informed consent to participate in the study was obtained from all patients prior to enrollment.
: This was an independent, investigator-initiated study supported by Boehringer Ingelheim (BI) Pharma GmbH & Co. KG, Germany. BI had no role in the design, analysis or interpretation of the results in this study. BI was given the opportunity to review the manuscript for medical and scientific accuracy as it relates to BI substance, as well as intellectual property considerations. J.G. received honoraria from TESARO, QUIRIS Healthcare, Ecker + Ecker, Dr. August Wolff, Roche, University Clinics Schleswig–Holstein, and RWTH Aachen University. J.-H.M. received honoraria from Astellas, Pfizer, Daiichi Sankyo, BMS, Celgene, Novartis, Jazz, and BeiGene. G.L. received research grants not related to this manuscript from AGIOS, AQUINOX, AstraZeneca, Bayer, Celgene, Gilead, Janssen, Morphosys, Novartis, Roche, and Verastem. G.L. received honoraria from ADC Therapeutics, Abbvie, Amgen, AstraZeneca, Bayer, BMS, Celgene, Constellation, Genmab, Gilead, Incyte, Janssen, Karyopharm, Miltenyi, Morphosys, NanoString, Novartis, and Roche. C.S. received honoraria from AbbVie, AstraZeneca, Astellas, BMS, Celgene, Jazz, Novartis, Pfizer and Roche. The remaining authors declare no competing financial interests.